How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/paroxysmal-supraventricular-tachycardia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Paroxysmal supraventricular tachycardia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Paroxysmal supraventricular tachycardia (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Paroxysmal supraventricular tachycardia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Adenocard	ADENOSINE	Astellas Pharma	Adenosine Receptor Agonist [EPC]	Adenosine receptor A3	1989-01-01
Cytovene	GANCICLOVIR	Roche Palo	Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor	Metabotropic glutamate receptor 1	1989-01-01
Cardizem	diltiazem	Generic (originally Tanabe Seiyaku)	Calcium channel blocker (non-dihydropyridine, benzothiazepine)	Voltage-dependent calcium channel gamma-1 subunit, Multidrug resistance protein 1, Solute carrier family 22 member 1	1982-11-05
Methoxamin	METHOXAMINE	GSK	methoxamine	Alpha-1A adrenergic receptor	1982-01-01
Adenosin	Adenosin	University of Roma La Sapienza		Phosphatidylinositol 4-kinase type 2-alpha, Phosphatidylinositol 4-kinase type 2-beta, Adenosine kinase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Paroxysmal supraventricular tachycardia
Astellas Pharma · 1 drug in Paroxysmal supraventricular tachycardia
GSK · 1 drug in Paroxysmal supraventricular tachycardia
Generic (originally Tanabe Seiyaku) · 1 drug in Paroxysmal supraventricular tachycardia
Roche Palo · 1 drug in Paroxysmal supraventricular tachycardia
University of Roma La Sapienza · 1 drug in Paroxysmal supraventricular tachycardia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Paroxysmal supraventricular tachycardia:

Cite this brief

Drug Landscape (2026). Paroxysmal supraventricular tachycardia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/paroxysmal-supraventricular-tachycardia. Accessed 2026-06-10.

Paroxysmal supraventricular tachycardia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing